UN PREMIO A SOSTEGNO DELLA RICERCA NEL CAMPO DELLA BATTERIOTERAPIA ORALE

 

“Dal 2010, ogni due anni la Farmagens Health Care e assegna un riconoscimento per l’impegno e i risultati ottenuti nelle ricerche in campo Farmacogenomico e Nutrigenomico.”

 

La FARMAGENS HEALTH CARE è oggi una delle più importanti realtà Internazionali dedita alla ricerca e allo sviluppo biotecnologico in diverse aree terapeutiche, come l’Apparato Cutaneo, l’Apparato Respiratorio, le Vie Urogenitali e il Tratto Gatrointestinale, che interessano in modo particolare la prevenzione e la cura della salute della donna.

Una divisione della FARMAGENS HEALTH CARE è totalmente dedicata alla ricerca, sviluppo e promozione di studi e protocolli terapeutici nelle diverse aree terapeutiche di interesse.

La FARMAGENS HEALTH CARE in collaborazione con una importante società di ricerca e produzione nel campo della NUTRIGENOMICA, ha istituito, a partire dal 2010, una borsa di studio per la ricerca nel campo della Batterioterapia Orale finalizzata ad incentivare ricerche in campo Farmacogenomico e Nutirgenomico con specifici focus sul ruolo del PROBIOMA UMANO e le correlazioni che possono influenzare patologie infiammatorie, alterazioni metaboliche e neoplasie con particolare riferimento agli aspetti che interessano la specificità femminile.

La borsa di studio è una iniziativa che viene riproposta ogni 3 anni attraverso una comunicazione rivolta alle società scientifiche nazionali ed internazionali maggiormente impegnate nella ricerca e nella clinica delle aree terapeutiche: Gastroenterologia, Dermatologia, Infezioni delle Vie Respiratorie, Oncologia e Ginecologia.

RICERCHE E STUDI RELATIVI ALLE BORSE DI STUDIO PRECEDENTI:

Gli studi premiati nell’anno 2016 sono stati condotti e coordinati dalla collaborazione tra:

Prof. Giuseppe Sarnelli, Università Federico II di Napoli;

Prof. Giuseppe Esposito, Università Federico II di Napoli;

Prof. Rosario Cuomo, Università La Sapienza di Roma;

Prof. Lu Jie, Harvard University

E sono rispettivamente:

  1. Biological Composition based on engineered Lactobacillus Paracasei subsp. Paracasei F19 for the biosynthesis of cannabinoids.

ABSTRACT

The invention provides a method for producing therapeutic cannabinoids characterized by administering to an host the probiotic Lactobacillus Paracasei subsp. Paracasei F19, genetically modified to produce and secrete cannabinoids from Cannabis sativa, in association with caproic acid, able to establish the enzymatic reactions of the biosynthetic pathway leading to the production of cannabinoids directly in situ in said host.

  1. Dietary Methods using Lactobacillus Paracasei subsp. Paracasei F19 as NAPE-PLD gene carrier for producing on demand PEA or OEA and relative biological dietary composition thereof.

ABSTRACT

Method enabling to modulate and customize the production of active lipids involved in exerting an antagonistic action to local inflammation and in modulating the mast cell reactivity, comprising the administering to an host the probiotic Lactobacillus paracasei subsp. Paracasei F19, genetically modified with a nucleotide vector comprising a nucleic acid encoding the human N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD), in association with lipid substrates and precursors, to influence the enzymatic reactions of said probiotic agent in the host.

The method is useful in the treatment of inflammatory bowel disorder and in the treatment of metabolic syndrome and for controlling of obesity.

Gli studi oggetto della ricerca sperimentale verranno finanziati dalla Borsa di Studio, ed avranno un importantissimo impatto e rilevanza nel campo della Farmacogenomica e Nutrigenomica.

 

Nel 2013 dal Dott. Nardone Gerardo e dalla Dott. ssa Debora Compare per il lavoro:

1)Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inihibitor-induced bowel symptoms: A randomized clinical trial.

Abstract

BACKGROUND:

Proton pump inhibitors may foster intestinal dysbiosis and related bowel symptoms.

AIM:

To evaluate the effect of Lactobacillus paracasei F19 on bowel symptom onset in patients on long-term proton pump inhibitors.

METHODS:

In this randomized, double-blind, placebo-controlled study, patients with typical gastroesophageal reflux disease symptoms receiving pantoprazole 40 mg/d for six months were randomly assigned to receive: (A) Lactobacillus paracasei F19 bid for three days/week for six months; (B) placebo bid for three days/week for six months; (C) Lactobacillus paracasei F19 bid for three days/week for three months and placebo bid for three days/week for the following three months; (D) placebo bid for three days/week for three months and Lactobacillus paracasei F19 bid for three days/week for the following three months. Bloating, flatulence, abdominal pain and bowel habit were assessed monthly.

RESULTS:

100/312 patients were enrolled. In the parallel groups, the treatment-by-time interaction affected bloating (p = 0.015), while Lactobacillus paracasei F19 treatment alone affected flatulence (p = 0.011). Moreover, the treatment-by-time interaction significantly affected the mean score of bloating (p = 0.01) and flatulence (p < 0.0001), the mean stool form (p = 0.03) and mean stool frequency/week (p = 0.016). Analysis of the cross-over groups, limited to the first three months because of carry-over effect, confirmed these results.

CONCLUSION:

Lactobacillus paracasei F19 supplementation prevents bowel symptom onset in patients on long-term proton pump inhibitors.

 

Nel 2010 dal Dott. Lucio Lombardo per i lavori:

1) New Insights into Lactobacillus and functional intestinal disorders.

Intestinal microflora can be considered as a ''dynamic system'' that actively interacts with the intestinal epithelium and the local immune system. It synthesizes antimicrobial substances (bacteriocins), vitamins (PP, B1, B6, B12), it produces a major intestinal nutrient (butyric acid) and interacts in a competitive fashion with the pathogens. Lactobacilli concentration (Gram+, Gram variable, facultative anaerobes) is generally decreased in irritable bowel syndrome (IBS) patients. This syndrome has, until recently been considered to be ''functional'', whereas, in fact, it may result from previous enteritis (in up to 31% of patients), featuring a persistent low-grade intestinal inflammation and a reduction in interleukin-10 (IL-10) concentration. Some Lactobacilli strains (e.g. L. paracasei subsp. paracasei) in vitro lead to normalisation of the hypercontractility of the smooth muscle cells. A growing body of clinical findings indicates that some ''genetically stable'' strains of Lactobacilli may be useful in the treatment, even long term, of IBS, and reduce the postoperative infection rate, especially in critically ill patients (orthotopic liver transplant, severe pancreatitis). However, some Lactobacilli, ''not genetically stable'', used in the treatment of neutropenic patients during chemotherapy and in pediatric patients submitted to gastrojejunostomy, have been reported to lead to bacteremia and endocarditis. These effects may be due to transfer of bacteria and genetic material. Therefore, the confirmed genetic stability and the fact that no antibiotic resistance occurs are fundamental requisites for the use of Lactobacilli in certain disorders of the gastrointestinal tract, such as, for instance, IBS. In conclusion, ''genetically stable'' Lactobacilli (L. paracasei subsp. Paracasei F19) have recently become available, representing an exiting new field in clinical studies and for treatment purposes, offering guarantees of safety also for long-term use. Careful personalized evaluation, as always in medical practice, is necessary in order to gain further insight into, and to validate with additional studies, the role of ''genetically stable'' Lactobacilli in the treatment of IBS

2) PPI Use and SIBO Predisposition or Cause?

info@farmagens.it